PMID- 28370183
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20220409
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
VI  - 118
IP  - 11
DP  - 2017 Nov
TI  - A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy 
      and Safety Assessment.
PG  - 3686-3695
LID - 10.1002/jcb.26015 [doi]
AB  - The mainstream treatments for non-melanoma skin cancer (NMSC) include 
      photodynamic therapy (PDT), surgery excision (SE), cryotherapy (CT), imiquimod 
      (IM), radiotherapy (RT), 5-fluorouracil (FU), and vehicle (VE). Our network 
      meta-analysis (NMA) was aimed at evaluating the efficacy and safety of these 
      seven treatments and providing superior ones. After searching the trials from 
      Embase and PubMed and screening with our criteria, we conducted the NMA with 
      software R 3.2.3 and STATA 13.0. Complete lesion response (CLR), complete lesion 
      clearance (CLC), cumulative recurrence probabilities (CRP), and adverse effects 
      (AEs) were considered as outcomes and displayed as odds ratios (ORs) and 95% 
      credible intervals (CrI). The surface under the cumulative ranking curve (SUCRA) 
      was calculated to rank each treatment on each index. The consistency of direct 
      and indirect evidence was also assessed by node-splitting and heat plot methods. 
      Data from 18 trials with 3706 patients were included. Both IM and SE were 
      demonstrated significantly higher CLR rate than VE (OR = 9.12, 95% 
      CrI = 1.92-47.5; OR = 26.1, 95% CrI = 1.92-347; respectively), while only IM was 
      proved to be statistically better than VE in CLC rate (OR = 7.03, 95% 
      CrI = 1.51-32.8). No significant difference was observed concerning CRP, and IM 
      was more likely to induce AEs than VE (OR = 4.44, 95% CrI = 1.58-13.9). The SUCRA 
      results indicated that SE was the treatment with best ranking in the entire three 
      efficacy indexes and a relatively high safety. Taking efficacy and safety into 
      account, our study recommended SE as the optimal regimen for NMSC with high 
      efficacy considering CLR, CLC, and CRP and moderate AEs when compared with other 
      interventions. J. Cell. Biochem. 118: 3686-3695, 2017. (c) 2017 Wiley Periodicals, 
      Inc.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Lv, Renrong
AU  - Lv R
AD  - Department of Burn and Plastic Surgery, Provincial Hospital Affiliated to 
      Shandong University, Jinan, 250021, Shandong, China.
FAU - Sun, Qian
AU  - Sun Q
AUID- ORCID: 0000-0003-4609-5925
AD  - Department of Obstetrics, Jinan Maternity and Child Care Hospital, Jinan, 250001, 
      Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20170620
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
RN  - 0 (Aminoquinolines)
RN  - P1QW714R7M (Imiquimod)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aminoquinolines/therapeutic use
MH  - Cryotherapy/methods
MH  - Fluorouracil/therapeutic use
MH  - Humans
MH  - Imiquimod
MH  - Melanoma
MH  - Photochemotherapy/methods
MH  - PubMed
MH  - Skin Neoplasms/*therapy
OTO - NOTNLM
OT  - EFFICACY; SAFETY
OT  - NETWORK META-ANALYSIS
OT  - NON-MELANOMA SKIN CANCER TREATMENTS
EDAT- 2017/04/04 06:00
MHDA- 2018/01/03 06:00
CRDT- 2017/04/04 06:00
PHST- 2017/01/11 00:00 [received]
PHST- 2017/03/27 00:00 [accepted]
PHST- 2017/04/04 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2017/04/04 06:00 [entrez]
AID - 10.1002/jcb.26015 [doi]
PST - ppublish
SO  - J Cell Biochem. 2017 Nov;118(11):3686-3695. doi: 10.1002/jcb.26015. Epub 2017 Jun 
      20.